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Acute kidney injury (AKI) after cardiac procedures and in
critically ill patients has been consistently associated with
increased cost of care, complications, permanent kidney
dysfunction, and higher mortality (1,2). There is an imme-
iate and present need to detect acute AKI before the rise in
erum creatinine (Cr) and the development of oliguria,
ecause by that time patients are often resistant to thera-
eutic interventions (3).
See page 1752
For decades, the rise in serum Cr has been the only
detectable sign of a reduction in glomerular filtration.
Creatinine has had the disadvantages of being linked to
creatine and the overall body muscle mass—hence, differing
according to body size in addition to the rate of renal
elimination (4). Furthermore, the kidney both filters and
ecretes Cr. Finally, the assays used to measure Cr have not
een standardized across laboratories; therefore, studies
eporting values from multiple centers have inherent varia-
ion in values attributed to differences in measurement
echnique (5). Cystatin C is a cysteine protease inhibitor
hat is synthesized and released into the blood at a relatively
onstant rate by all nucleated cells. It is freely filtered by the
lomerulus, completely reabsorbed by the proximal tubule,
nd not secreted into urine. Its blood levels are not affected
y age, sex, race, or muscle mass; thus, it seems to be a better
ndicator of glomerular function than serum Cr in patients
ith CKD. However, in AKI, it rises only slightly before
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From the †St. John Providence Health System, Providence Park Heart Institute,
ovi, Michigan; and the ‡St. John Hospital and Medical Center, Detroit, Michigan.rhe authors have reported that they have no relationships to disclose.erum Cr (6). The field of nephrology in the United States
as been devoid of approved blood or urine markers of AKI,
nlike cardiac biomarkers indicating myocardial injury and
verload (troponin, creatine kinase myocardial band, and
atriuretic peptides). The concept of measuring markers of
he acute injury process is crucial to the early upstream
dentification of AKI before there is serious loss of organ
unction (7). Ideally, markers that give insight into the
athophysiologic mechanisms for AKI would be desirable,
ecause there could be tandem development of therapeutic
pproaches.
Neutrophil gelatinase-associated lipocalin (NGAL), oth-
rwise known as siderocalin or lipocalin-2, is normally
ecreted by renal tubular cells, lymphocytes, and cardiomy-
cytes and is a physiologic response to the presence of
atalytic (labile, poorly liganded) iron in the cytosol or
ericellular space that itself is liberated from organelles as a
esult of ischemic or toxic injury. It is a 25-kDa protein that
cts as a natural siderophore that scavenges cellular and
ericellular labile iron, thus reducing its availability for
acterial growth. Iron is the most common metal element in
he human body, and there are elaborate transport (heme,
ransferrin, ferritin, ferroportin, electron transport chain)
nd management systems for its use in a variety of critical
ellular systems, including oxygen transport and cellular
espiration (8,9). It has been recently understood that the
rocess of oxidative stress resulting in cell dysfunction,
ccelerated apoptosis, and death is reliant on the cytosolic
nd extracellular presence of labile or catalytic iron, liberated
rom its binding proteins. There are several steps in gener-
tion of reactive oxygen species. Oxygen might be reduced,
orming superoxide anion, which can undergo reduction by
uperoxide dismutase to form hydrogen peroxide—which
tself can then be reduced through several pathways. The net
eaction is slow, and in the presence of reduced transition
etals such as ferric iron (Fe3), a Haber–Weiss reaction
esults in the rapid formation of the highly damaging
ydroxyl radical from the superoxide anion. Likewise, in the
resence of ferrous iron (Fe2), a Fenton-type reaction
onverts hydrogen peroxide to the hydroxyl radical. It has
een theorized that a common element to all forms of
xidative stress to the heart and kidneys involves the
vailability of unbound or poorly liganded iron (10). With
he bleomycin detectable assay, Lele et al. (9) have recently
emonstrated the release of catalytic iron into the blood in
atients with acute coronary syndromes. In this study, the
ppearance of catalytic iron preceded the rise in serum
roponin and had an area under the receiver operating
haracteristic curve for the detection of acute myocardial
nfarction over 0.90. Local cellular and tissue availability of
atalytic iron might determine the degree and severity of
rgan injury in the setting of most hypoxic and other toxic
nsults (8). Therefore, a putative final common pathway for
ommon sources of organ injury including ischemia, neu-
ohormonal activation, chemotoxicity, and sepsis involves
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April 26, 2011:1762–4 NGALthe loss of control over normal iron management and the
transient tissue and organ system exposure to catalytic iron,
which is attenuated by NGAL (11).
In this issue of the Journal, Haase et al. (12), as part of a
revious larger meta-analysis, identified and invited authors
f 18 published studies of clinical outcomes of AKI patients
ccording to NGAL (measured either in the blood or urine)
nd Cr status. Of those, 7 authors returned complete
atasets consisting of 1,217 patients (11). The major find-
ngs were that 41.1% of patients diagnosed with AKI would
ave been missed with Cr alone. Compared with patients
eclared negative with respect to both NGAL and Cr
esults, those positive for both had a 2-fold longer stay in
he ICU and in-hospital, more dialysis initiation, and a
ripled in-hospital mortality. In the discordant groups,
GAL tended to identify increased risk when the Cr was
ot significantly changed, with the greatest value being in
he NGAL() but Cr() group. These data suggest that a
arker of the renal response to oxidative stress (NGAL)
nd damage in addition to a marker of decreased renal
ltration function (Cr) are complementary in the diagnosis
nd prognosis of AKI across a variety of hospitalized
opulations.
The reason this study is important is, first, because it
onsistently showed prognostic significance of NGAL value
n a large number of AKI patients with wide range of
linical situations, including critically ill patients and post-
ardiac surgery patients as well as pediatric and adult
opulation. Neutrophil gelatinase-associated lipocalin typi-
ally detected AKI 36 to 48 h earlier than Cr, thus opening
p a possibility of therapeutic interventions of AKI. Second,
his analysis identified new important subgroups of AKI
atients according to NGAL and Cr values, which seem to
e complementary. Specifically, NGAL()/Cr() patients
ight have pre-renal azotemia or tubulo-glomerular feed-
ack mechanisms at work without acute tubular necrosis,
hich might require totally a different therapeutic approach,
s opposed to those who have started to secrete increased
uantities of NGAL. Conversely, identification of the
GAL()/Cr() patient is a critical step forward, because
he production of NGAL signals a response to catalytic
ron-dependent oxidative stress before there is a measurable
ecrement in organ function. We recognize that a short-
oming of NGAL as a singular test is that baseline levels rise
ith chronic renal disease, and thus it becomes a marker of
isease progression and might lose its ability to detect AKI
rom an elevated baseline in more seriously ill populations
13,14).
With the advent of NGAL and the detection of AKI
ithin a few hours of initiation, it is now conceivable to test
reventive or immediate therapeutic interventions. The
hange in NGAL might serve as an experimental marker in
hase 2 trials of preventive approaches including catalytic
ron chelators (e.g., deferiprone), other antioxidant agents
uch as N-acetylcysteine (for contrast exposure), or B-type
atriuretic peptide in the perioperative period after cardiacurgery (15,16). Once NGAL has started to rise in critical
are and post-surgical scenarios, treatment trials could be
rganized to test forms of continuous renal replacement
herapy (CRRT) in the period of time surrounding the renal
nsult. Conceptually, use of CRRT would provide 3 impor-
ant protective mechanisms that cannot be achieved phar-
acologically: 1) ensures euvolemia and avoids hypo- or
yper-volumia; 2) provides sodium and solute (nitrogenous
aste products) removal; and 3) by both aforementioned
echanisms, it might work to avoid both passive renal
ongestion and a toxic environment for the kidneys and
llow their optimal function during a systemically vulnerable
eriod (17). Despite these advantages, there remains a lack
f clinical trial data supporting CRRT or other forms of
xtracorporeal solute removal, largely because the interven-
ion is applied too late in the clinical course where the
etection of AKI is dependent on the rise in serum Cr and
evelopment of volume overload.
The identification of NGAL as a protective siderophore
nd its role in limiting the ability of catalytic iron to
ropagate oxidative stress reactions in acute organ injury
yndromes seems to be a major advance. Additional bio-
arkers, including kidney injury molecule-1, interleukin 18,
iver-type fatty acid binding protein, renal tubular enzymes,
nd multiple proprietary markers under investigation, might
dd to the internal validity and assist in understanding the
ime course and recovery of AKI. These markers used
ogether as a panel might be particularly valuable in the
opulation where Cr has not yet changed. The discovery of
GAL and its clinical introduction in Europe last year has
merged as an ideal circumstance in the biomarker field,
here both diagnostic and therapeutic advances are on the
orizon.
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